Myelodysplastic Syndromes | Topics

 
Venetoclax Combination Earns FDA Breakthrough Therapy Designation for Higher-Risk MDS
July 21, 2021

The combination of venetoclax and azacitidine will be considered as a treatment for patients with newly diagnosed, higher-risk myelodysplastic syndrome.

Improved OS Seen With Momelotinib-Associated Transfusion Independence at 24 Weeks in Myelofibrosis
June 21, 2021

Data presented from the phase 3 SIMPLIFY 1 and SIMPLIFY 2 trials at 2021 EHA indicate success of momelotinib in extending overall survival in patients with myelofibrosis who achieve transfusion independence.

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia
February 24, 2021

A study published in The Lancet Hematology found an increased risk of developing myelodysplastic syndrome and acute myeloid leukemia when patients with cancer were treated with PARP inhibitors compared with placebo.